Introduction
Oral squamous cell carcinoma (OSCC) is one of the most common forms of cancer, which accounts for over 30% of all cancers that are reported in India (Coelho et al., 2010) . Despite the therapeutic advances that have been developed in the recent past, the five year survival rate been known to be induced by interferons, its observation in OSCCs suggests that other signaling components of the interferon pathway regulating diverse functions are also expected to contribute towards carcinogenesis. Indeed, genetic anolmalies of the interferon regulatory factors (IRFs), which belong to a family of transcription factors, have been identified in several carcinomas. Loss of expression of IRFs due to epigenetic modification of respective promoter regions have been observed with IRF5/7 in lung cancer (Li et al., 2011) , IRF6 in cutaneous cancer (Botti et al., 2011) and IRF8 in multiple myeloma (Tshuikina et al., 2008) , nasopharyngeal, esophageal (Lee et al., 2008) and colon cancers (McGough et al., 2008) . Most of the IRFs share among themselves a highlyconserved N-terminal helix-turn-helix DNA-binding domain and a C-terminal protein binding domain called as IRF associated domain (IAD) (Ozato et al., 2007) . While the N-terminal DNA-binding domain is essential for IRF proteins to bind with the respective promoter region of genes it regulates, the C-terminal IAD is required for protein-protein interactions (Tamura et al., 2008; Savitsky et al., 2010) . Of the nine IRFs (IRF1 to IRF9) that have been reported so far, IRF6 is known to play a vital role in the development of craniofacial region, by regulating cellular differentiation and proliferation (Zucchero et al., 2004) . Mutational alterations in the coding regions of IRF6 gene were first identified in subjects with van der Woude syndrome (VWS), which is known to be the most common of all the Mendelian malformation syndromes (Zucchero et al., 2004) . Subjects with VWS have either cleft lip, cleft palate or cleft lip with cleft palate (CL/CP/ CLP) and importantly, a labial pit that distinguishes VWS from non-syndromic CL/CP/CLP (Zucchero et al., 2004) . The exon 7 of IRF6 gene encodes for major region of the C-terminal IAD region and hence mutations within this region may be expected cause functional impairment. Indeed, a single point mutation that causes conversion of GTC to ATC creating valine to isoleucine substitution at position 274 in IRF6 protein has been found to be significantly associated with cleft in several populations (Mangold et al., 2011; Salahshourifar et al., 2011; Stuppia et al., 2011) . The identification of loss of IRF6 expression due to promoter hypermethylation of IRF6 in cutaneous squamous cell carcinomas and function impairing mutations in exon 7 of IRF6 in CL/CP/CLP prompted us to investigate, whether such mutations occurred in well differentiated OSCC lesions.
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Materials and Methods
Study design and subjects A cross sectional study was designed to investigate the occurrence of mutation in the conserved protein binding domain of IRF6 in thirty two OSCC genomic DNA samples that were obtained earlier (Rajendran et al., 2013; Rupesh et al., 2013) . The study was approved by institutional ethics committee (IEC) and was conducted at the Human Genetics Laboratory at Sree Balaji Medical and Dental College and Hospital, Bharath University. As mentioned in earlier publication (Rajendran et al., 2013; Rupesh et al., 2013) , patients who were found to have lesion associated pain, and/or medical conditions unrelated to OSCC like diabetes mellitus, hypertension or infectious diseases were excluded from the study.
Polymerase chain reaction and direct sequencing
Exon 7 of the IRF6 gene was amplified with intronic primers that were designed to amplify the entire exon 7 along with splice acceptor and donor sites. The following primer sequences were used: Forward -AGGACTCTCACTGTCAT, Reverse -AGACCAGTACACCTTGCA. The exon 7 was amplified with 25ng of genomic DNA under the following conditions: after denaturing the total genomic DNA at 94°C for 4 min, the exon was amplified for 25 cycles with denaturing at 95°C for 45 sec, annealing at 55°C for 50 sec, and extension at 72°C for 1 min, followed by a final extension at 72°C for 5 min. Subsequently, the amplified region of exon 7 from all OSCC samples were run in a 1.2% agarose gel and eluted with Genelute DNA gel elution kit (Sigma Aldrich, cat# NA1111). 10ng of the eluted PCR amplicon was subjected to direct sequencing (Genetics Lab, Madras Diabetes Research Foundation, Chennai, India) to identify mutations.
Results
The exon 7 of IRF6 gene encodes for the major protein binding domain called IAD (IRF Associated Domain), with which it interacts to form homo-and hetero-dimers with intracellular proteins. Since mutations within the conserved domain are likely to affect the functional aspect of IRF6 protein, we investigated for the occurrence of mutations within exon 7 in OSCC tissue samples. Direct sequencing analysis identified a point mutation in 9% (3 of 32) of OSCC samples. The wild type codon TTC at position 252 in IRF6, which encodes for phenylalanine amino acid was found to be mutated to TAC coding for tyrosine (F252Y) (Figure 1 ). The F252Y mutation always occurred in heterozygous condition along with its wild type codon, phenylalanine.
Discussion
Genetic anomalies in the components of the interferon signaling pathway are beginning to be identified as clinically relevant early cancer detection biomarkers. In the present study, we have investigated the chromosomal DNA isolated from tissues that were excised from thirty two OSCC patients at the time of surgery, to investigate the occurrence of mutational alteration in the IRF6 gene. We analyzed the exon 7 of IRF6 as it codes for the major region of the C-terminal protein-protein interaction domain. Direct sequencing analysis identified a single point mutation within the coding region of exon 7 in 9% (3/32) of OSCC samples. The mutation resulted in the conversion of phenylalanine amino acid to tyrosine at DOI:http://dx.doi.org/10.7314/APJCP.2013.14.11.6803 A Novel IRF6 Mutation in Oral Squamous Cell Carcinomas position 252 in IRF6 (F252Y). The occurrence of F252Y mutation in only 9% of OSCC samples suggests that the mutation may not be as prevalent as those that occurs in other genes such as H-ras for example, in which mutations have been in up to 20%, especially in OSCC lesions from India (Murugan et al., 2012; Jayaraman et al., 2013) .
Phenylalanine to tyrosine mutation has also been observed in other systems as well; where in the above amino acid substitution has been shown to interfere with the function of the protein. (Park et al., 1997) . Hence the IRF6 mutant (F252Y) identified in the present study is predicted to have an impaired substrate or effector binding ability, which thereby might have played a role in carcinogenesis. However, it is important to note that the above the interpretation is being made solely based on the published evidence, which however, requires an in vivo cell based assay to confirm the functional impairment. Of significant interest is the observation that, mutation of a tyrosine residue within the active site of E coli Ddl to phenylalanine caused gain of function of Ddl protein (Park et al., 1997) , which clearly reiterates, albeit indirectly, the potential loss of function that is predicted with the F252Y mutation in IRF6.
Although cancerous lesions are managed surgically, postsurgical palliative chemotherapy with or without radiotherapy remains to be the preferred line of treatment in routine practice. Interestingly, many chemotherapeutic agents have been observed to cause an increase in the expression of IRFs. For example, treatment of cells with adriamycin, mitomycin C, cisplatin or etoposide causes upregulation of IRF7 (Kim et al., 2000) . On the other hand, ectopic expression of IRFs, IRF1 for example in gastric cancer cells have been shown to increase the sensitivity of those cells to 5-fluorouracil relative to untreated control cells (Gao et al., 2012) . While these studies clearly highlight the emerging importance of the components of interferon pathway in the development and treatment of carcinomas, it becomes critical to note that our finding of a mutation in IRF6 carries significant clinical value as incidence of resistance of cancer cells to chemotherapeutic agents have been reported especially in cells carrying mutant genes. For example, cancer cells expressing mutant epidermal growth factor receptor (EGFR) molecules have been found to be resistant to chemotherapeutic drugs (Sigismund et al., 2012) . Hence it is possible that the F252Y mutation identified in the three OSCCs in the present study may be expected to confer resistance to chemotherapeutic drugs as well. However, further in-depth explorations are required in order to confirm the above observations. Nevertheless, the finding of a novel mutation IRF6 F252Y is clinically significant as the mutation is being reported for the first time in OSCC lesions, and that the significance of this may increase when the epigenetic modification of IRF6 promoter region is also analyzed in the same samples.
